The market is categorized by product, with connected inhalers generating USD 4.3 billion in revenue in 2024 and set to grow at a CAGR of 16.8%. The rising incidence of asthma and chronic respiratory diseases is driving demand for these devices, which offer real-time data tracking and usage monitoring, improving treatment adherence. The integration of sensors and digital applications enhances patient engagement and symptom management, further propelling market growth.
By application, the neurological disorders segment held a 39.4% revenue share, reaching USD 4.7 billion in 2024. The increasing occurrence of Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis is generating demand for advanced drug delivery solutions that enhance treatment efficacy. These technologies improve drug administration accuracy, optimizing therapeutic outcomes and reducing treatment-related challenges. The ability to deliver targeted therapies for complex neurological conditions contributes significantly to segment growth.
The market is segmented by route of administration into injectables, inhalation, and oral drug delivery. The injectable segment led with USD 7.6 billion in revenue in 2024, driven by advancements in materials science, nanotechnology, and smart sensors. These innovations enhance drug delivery, monitoring, and customization, ensuring precise dosing and improved treatment outcomes. Regulatory approvals from agencies like the U.S. FDA are supporting the commercialization of these solutions, accelerating market growth.
Hospitals represent the largest end-use segment, generating USD 5.5 billion in revenue in 2024. The increasing adoption of smart drug delivery technologies in hospitals is improving medication management, ensuring better treatment adherence, and optimizing patient care. Growing hospitalization rates, advancements in healthcare infrastructure, and investments in smart medical devices are driving segment expansion.
Regionally, North America led the smart drug delivery systems market, reaching USD 5.5 billion in 2024, with projections to hit USD 22.2 billion by 2034. The U.S. dominated the regional market with USD 5 billion in revenue in 2024. Strong collaborations between pharmaceutical and medical device companies, along with regulatory support for innovative medical technologies, are propelling market growth in the region.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Companies Mentioned
The companies featured in this Smart Drug Delivery Systems market report include:- Amiko Digital Health
- Becton, Dickinson and Company
- Biocorp
- Elcam Medical
- Johnson & Johnson
- Medtronic
- Merck
- Nemera
- Novo Nordisk
- Pfizer
- Phillips-Medisize
- Portal Instruments
- Teva Pharmaceutical Industries
- West Pharmaceutical Services
- Ypsomed

